As part of its ongoing ambition to promote patient access to its unique treatment, Arthrosamid®, across Europe, Contura Orthopaedics Ltd has announced a new partnership with Hogan Healthcare, one of Ireland’s independent medical device distributors.
Arthrosamid® is a polyacrylamide hydrogel developed by Contura International Ltd. as a long-lasting intra-articular injection approved in Europe for the treatment of knee osteoarthritis (OA). The treatment has the potential to change the present care pathway for managing OA, which affects around one in four adults in Ireland aged over 60 [1] (over 400,000 people) [2] and current treatments are not long lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of OA treatments on offer to meaningfully help patients – until now.
Consisting of 2.5% cross-linked polyacrylamide and 97.5% non-pyrogenic water, a 6ml dose of Arthrosamid® is injected into the joint space to cushion the knee and relieve pain in one single treatment [3]. Patients can expect to see improved mobility and pain relief within days where the effect is long lasting [4]. Arthrosamid® becomes embedded in the synovial membrane, providing increased cushioning and bringing both pain relief and improved mobility to patients suffering from knee osteoarthritis.
The first procedure to be carried out in Ireland took place on Friday, April 22 treating a patient who was likely to be ineligible for knee replacement surgery and, as such, was seeking long lasting and non-invasive pain relief. The patient will now be followed up closely by the clinician to observe the benefits – and it is hoped this first case study will help to pave the way for further clinics and hospit